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Tricuspid valve regurgitation (TR) is usually accom-panied by advanced mitral valve disease. It may be
present in 10% to 50% of patients with severe mitral
stenosis or regurgitation.1 In a majority of patients,
this condition is functional rather than organic, the
result of pulmonary hypertension and right ventricular
dilatation, leading to dilatation of the tricuspid anu-
lus.2 As spontaneous regression of functional TR after
repair of the mitral lesion is almost impossible in cases
of severe TR, surgical repair of TR has also been
reported to be inevitable.1,3 Although tricuspid valve
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annuloplasty, such as semicircular or ring annuloplas-
ty, has been the most common surgical modality for
severe TR,4-6 tricuspid valve replacement (TVR) has
been performed to prevent residual TR. However,
TVR can result in prosthetic valve thrombus and pan-
nus formation, necessitating late reoperation.7 A spe-
cific variety of TVR, known as tricuspid valve supra-
annular implantation,8 has been performed in our
hospital for more than a decade. Tricuspid valve
supra-annular implantation is characterized by a reli-
able reduction of the tricuspid anulus without fatal
arrhythmias or thromboembolism, while preventing
residual TR by preserving the native tricuspid valve
and implanting the bioprosthesis in the supra-annular
position. The aim of this study was to investigate the
long-term outcome of tricuspid valve supra-annular
implantation in patients with severe TR complicated
by advanced mitral valve disease.
Patients and methods
Patients. We studied 88 patients who had advanced mitral
valve disease and severe TR and who underwent mitral valve
replacement (MVR) and tricuspid valve supra-annular
implantation at Mitsui Memorial Hospital between 1984 and
1998. The mean patient age at operation was 57 ± 11 years,
and the patients were followed up for an average of 7.2 ± 4.5
years after the operation (range 0-14.6 years), total follow-up
being 643.1 patient-years. Follow-up was 97.7% (86/88)
complete. The surgical indication for tricuspid valve supra-
annular implantation was a TR grade of 4/4 as evaluated by
right ventriculography or Doppler echocardiography.
Operative technique. With the patient under general anes-
thesia, the ascending aorta and both venae cavae were cannulat-
ed through a median sternotomy, and cardiopulmonary bypass
was established. After moderate systemic hypothermia was
reached, the ascending aorta was crossclamped and cold crys-
talloid cardioplegic solution was administered antegradely.
MVR was performed with a bioprosthesis or mechanical valve
through a conventional left atriotomy, after which the right atri-
um was opened and the tricuspid valve was thoroughly exam-
ined. After 2-0 Ticron (Cyanamid of Great Britain, Ltd,
Gosport, United Kingdom) interrupted suture reinforced with a
small hollow tube made of expanded polytetrafluoroethylene
was placed around the anulus, avoiding the triangle of Koch, a
bioprosthesis 31 or 33 mm in diameter (Carpentier-Edwards or
Carpentier-Edwards pericardial valve; Baxter Healthcare Corp,
Edwards Division, Irvine, Calif) was implanted in the supra-
annular position. This procedure resulted in placing the coro-
nary sinus on the right ventricular side (Fig l). All patients
received warfarin after the operation as an anticoagulant and
were followed up by Doppler echocardiography after discharge.
Measurements. We evaluated mortality, its causes, com-
plications due to thromboembolism or arrhythmias, the sur-
vival, freedom from structural valve deterioration (SVD), and
freedom from reoperation. Echocardiography was used to
examine the native tricuspid valve, thrombus formation
between the native tricuspid valve and the implanted bio-
prosthesis, residual TR, and mean velocity between the bio-
prosthesis and native valve.
Statistics. Survival and freedom from SVD and from reoper-
ation were expressed as mean ± standard error of the mean, and
other figures were mean ± standard deviation. Survival and
freedom from SVD and from reoperation were determined by
the Kaplan-Meier method. Correlations between the groups
were determined by the Pearson correlation coefficient. All
analyses were performed with the StatView version 4.5 statisti-
cal package (Abacus Concepts Inc, Berkeley, Calif).
Fig 1.  Schema of tricuspid valve supra-annular implantation.
A-V, Atrioventricular.
Fig 2. Overall survival. The overall survivals at 5, 10, and 14
years after the operation were 88.3% ± 3.5%, 81.2% ± 4.7%,
and 69.2% ± 7.7%, respectively. The numbers of patients
alive at 5, 10, and 14 years were 78, 74, and 71, respectively.
Results
Overall survival.  Three patients died within 30 days
of the operation and 3 died during hospitalization,
yielding operative and hospital mortalities of 3.4% and
6.8%. The mode of death was cardiac failure in 3
patients and multiple organ failure in 3. Twelve patients
died in the late postoperative period. One patient died
of a cardiogenic cause, and 9 died of noncardiogenic
causes: stroke (n = 4), multiple organ failure (n = 3),
and neoplasm (n = 2). In 2 others, the cause was
unknown. Overall survival at 5, 10, and 14 years after
the operation was 88.3% ± 3.5%, 81.2% ± 4.7%, and
69.2% ± 7.7%, respectively (Fig 2).
Freedom from SVD and from reoperation.
Freedom from SVD 14 years after the operation was
100% (Fig 3). Reoperation was required in 2 cases, and
freedom from reoperation was 88.5% ± 9.4% at 14
years (Fig 3). The cause of reoperation was pannus for-
mation on all cusps, which resulted in severe TR due to
chordal shortening in 1 case, and infectious endocardi-
tis in another. The vegetation extended under the cusps
of the bioprosthesis.
Echocardiographic findings.  Neither atrophic nor
stenotic changes were found on the native tricuspid
valve in any patient. The mean velocity between bio-
prosthesis and native tricuspid valve was 1.4 ± 0.2 m/s,
and no tricuspid stenosis was found. No thrombus for-
mation was observed between the implanted biopros-
thesis and the native tricuspid valve in any patient.
Postoperative TR at discharge was 0.2 ± 0.1 grade
and that at long-term follow-up was 0.9 ± 0.1. The
residual TR was less than grade 1/4 at 14 years after the
operation.
Thromboembolism and postoperative arrhyth-
mias. There was no case of obvious pulmonary
embolism. No thrombus formation was present on the
cusps in the explanted 2 bioprostheses. Anti-
coagulation-related bleeding occurred in 2 patients
who died of cerebral bleeding at 1 year and 12 years
after the operation. Minor cerebral infarction was
found in 2 other patients. Although spontaneous ven-
tricular tachycardia occurred in 3 patients, temporary
atrioventricular block in 2, and atrial fibrillation
bradycardia in 1, neither complete atrioventricular
block nor fatal arrhythmias occurred during the post-
operative periods. Late pacemaker implantation was
not necessary.
Discussion
TR may be functional or organic. Functional TR is
commonly caused by severe mitral valve stenosis or
regurgitation, both of which lead to dilatation of the
right ventricle and the tricuspid anulus. Organic TR
may be caused by rheumatic fever, trauma, or suba-
cute bacterial endocarditis. Secondary TR generally
resolves after a successful mitral valve operation if
the TR grade is not severe.4 Ring annuloplasty and
suture annuloplasty have been the most common sur-
gical modalities for severe TR.4,5,9 However, tricus-
pid valve  supra-annular implantation has been per-
formed in our hospital for patients with severe TR
complicated by advanced mitral valve disease
because of its reliability, little residual TR, lack of
complications related to fatal arrhythmias and throm-
boembolism, and simplicity of the procedure.
Tricuspid valve supra-annular implantation differs
from orthotopic TVR in its preservation of the native
tricuspid valve and implantation of the bioprosthesis
in the supra-annular position.
Tricuspid annuloplasty should be selected for moder-
ate to severe TR because the clinical results for ring
annuloplasty have been reported to be acceptable for
clinical use.9 However, in some cases it is not advisable
and may not completely resolve severe TR. For patients
with congestive liver dysfunction caused by severe TR,
it is controversial which procedure is more effective to
prevent liver failure.10
Prosthetic valve thrombus, pannus formation, and
pacemaker insertion are the long-term problems of
TVR.7,11 However, with regard to thromboembolism
and pannus formation, the long-term results of tricus-
pid valve supra-annular implantation appear to be bet-
ter than those of TVR.7,11 Valve replacement with a
bioprosthesis, not a mechanical valve, may reliably
prevent thromboembolism. Furthermore, implantation
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Fig 3.  Freedom from SVD and from reoperation. Freedom
from SVD was 100% (dotted line) and freedom from reoper-
ation was 88.5% ± 9.4% at 14 years after the operation (solid
line).
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of a bioprosthesis in the supra-annular tricuspid posi-
tion appears not to cause fatal arrhythmic complica-
tions. Late pacemaker insertion was reported to occur
in 6% of patients who underwent MVR and TVR, and
the actuarial incidence increased 25% up to 10 years.11
In our series, however, no pacemaker insertion was
required. This excellent outcome is the result of the
method of implanting the bioprosthesis.
In general, the durability of bioprostheses in the
mitral position has not been satisfactory when com-
pared with that of mechanical valves, especially in
younger patients.12,13 On the other hand, bioprosthe-
ses such as the Hancock valve (Medtronic, Inc,
Minneapolis, Minn) and the Carpentier-Edwards
pericardial valve in the tricuspid position have pro-
vided good long-term outcomes with a low incidence
of SVD and reoperation.14,15 Freedom from SVD 14
years after the operation was 100%, a significant
improvement compared with the previous reports on
this procedure.14,15 Critical issues related to long-
term follow-up include bioprosthesis-related throm-
boembolism in the pulmonary circulation, weakness
of the right atrial wall at the implantation site, and the
status of the native tricuspid valve, such as the pres-
ence of cusp calcification or atrophic change. As our
follow-up data on tricuspid valve supra-annular
implantation show that this procedure largely
resolves these problems, tricuspid valve supra-annu-
lar implantation is recommended as the appropriate
procedure for patients with severe TR complicated by
advanced mitral valve disease.
In summary, we examined the outcomes of MVR
and tricuspid valve supra-annular implantation in 88
patients with severe TR complicated by advanced
mitral valve disease between 1984 and 1998. The
procedure’s simplicity, the good long-term durability
of the bioprosthesis, and the absence of complica-
tions of fatal arrhythmias and pulmonary throm-
boembolism indicate that tricuspid valve supra-annu-
lar implantation is a useful procedure for patients
with severe TR complicated by advanced mitral valve
disease.
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